TABLE 2.
Characteristic | Odds ratio | p‐value | 95% confidence interval | |
---|---|---|---|---|
Lower bound | Upper bound | |||
Sex | ||||
Male | Ref. | |||
Female | 1.50 | 0.040 | 1.02 | 2.21 |
Age group | ||||
0 year | Ref. | |||
1–2 years | 0.63 | 0.118 | 0.35 | 1.13 |
3–5 years | 0.82 | 0.556 | 0.43 | 1.58 |
6–11 years | 1.13 | 0.670 | 0.65 | 1.98 |
12–17 years | 0.92 | 0.821 | 0.47 | 1.82 |
Immunosuppressants, immunodeficiency or chemo | ||||
No | Ref. | |||
Yes | 1.65 | 0.451 | 0.45 | 6.05 |
Hospitalization | ||||
No | Ref. | |||
Yes, without intensive care | 6.87 | <0.001 | 4.34 | 10.89 |
Yes, with intensive care | 9.60 | <0.001 | 2.77 | 33.27 |
Pyrexia (≥38.0/≥100.4°C/°F) | ||||
No | Ref. | |||
Yes | 1.84 | 0.011 | 1.15 | 2.96 |
Upper respiratory tract infection | ||||
No | Ref. | |||
Yes | 1.08 | 0.730 | 0.71 | 1.65 |
Diarrhea and/or vomiting | ||||
No | Ref. | |||
Yes | 1.05 | 0.822 | 0.67 | 1.64 |
Lower respiratory tract infection | ||||
No | Ref. | |||
Yes | 0.34 | 0.007 | 0.16 | 0.74 |
Headache | ||||
No | Ref. | |||
Yes | 0.88 | 0.746 | 0.42 | 1.87 |
Chest X‐ray abnormalities | ||||
No | Ref. | |||
Yes | 4.40 | <0.001 | 1.99 | 9.71 |
Oxygen support, mechanical ventilation and/or CPAP | ||||
No | Ref. | |||
Yes | 2.21 | 0.050 | 1.002 | 4.88 |
Administration of systemic corticosteroids | ||||
No | Ref. | |||
Yes | 4.39 | <0.001 | 2.01 | 9.58 |
MIS‐C diagnosis | ||||
No | Ref. | |||
Yes, w/o cardiac involvement | 10.35 | 0.050 | 1.005 | >100 |
Yes, w/ cardiac involvement | 45.48 | 0.011 | 2.44 | >100 |
Center | ||||
Hospital San Bartolomé (PE) | Ref. | |||
Hospital Nacional de Niños (CR) | 0.58 | 0.034 | 0.34 | 0.96 |
Hospital Isidoro Iriarte (AR) | 0.25 | <0.001 | 0.14 | 0.46 |
Hospital Edgardo Rebagliati Martins (PE) | 0.04 | 0.014 | 0.00 | 0.53 |
Hospital Pablo Tobón Uribe (CO) | 0.05 | <0.001 | 0.01 | 0.25 |
Clínica Jasmédica (PE) | 1.48 | 0.466 | 0.51 | 4.28 |
Hospital General Regional 200 Tecámac (MX) | 12.24 | 0.045 | 1.06 | >100 |
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.